Asterias Biotherapeutics Inc (NYSE:AST) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,803,537 shares, an increase of 11.5% from the August 15th total of 2,515,145 shares. Based on an average daily volume of 89,674 shares, the short-interest ratio is currently 31.3 days. Approximately 10.2% of the shares of the company are short sold.
Several equities analysts recently commented on the company. HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, July 17th.
Asterias Biotherapeutics (NYSE:AST) opened at 3.25 on Friday. The stock’s market cap is $162.43 million. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $3.34. Asterias Biotherapeutics has a 1-year low of $2.83 and a 1-year high of $5.80.
Asterias Biotherapeutics (NYSE:AST) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. The business had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.25 million. Equities analysts expect that Asterias Biotherapeutics will post ($0.62) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. State Street Corp grew its position in Asterias Biotherapeutics by 24.1% in the 2nd quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after purchasing an additional 63,773 shares during the period. Teachers Advisors LLC grew its position in shares of Asterias Biotherapeutics by 13.1% during the 2nd quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 6,714 shares during the period. California State Teachers Retirement System grew its position in shares of Asterias Biotherapeutics by 4.6% during the 2nd quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,100 shares during the period. Finally, Family Management Corp grew its position in shares of Asterias Biotherapeutics by 15.6% during the 2nd quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 6,416 shares during the period.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.